Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of BAY2927088 in advanced EGFR- and/or HER2-mutant non-small cell lung cancer
NL-OMON58818Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Started Apr 2023; status: active, not recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58818.